ID: ALA5201719

Max Phase: Preclinical

Molecular Formula: C23H24Cl2N8

Molecular Weight: 483.41

Associated Items:

Representations

Canonical SMILES:  Nc1nc(NCCc2c[nH]c3ccccc23)nc(N2CCN(c3cccc(Cl)c3Cl)CC2)n1

Standard InChI:  InChI=1S/C23H24Cl2N8/c24-17-5-3-7-19(20(17)25)32-10-12-33(13-11-32)23-30-21(26)29-22(31-23)27-9-8-15-14-28-18-6-2-1-4-16(15)18/h1-7,14,28H,8-13H2,(H3,26,27,29,30,31)

Standard InChI Key:  KMXCBWFCHIVUJL-UHFFFAOYSA-N

Associated Targets(Human)

Serotonin 1a (5-HT1a) receptor 14969 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serotonin 2a (5-HT2a) receptor 14758 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serotonin 6 (5-HT6) receptor 9749 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serotonin 7 (5-HT7) receptor 5576 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Dopamine D2 receptor 23596 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 483.41Molecular Weight (Monoisotopic): 482.1501AlogP: 4.22#Rotatable Bonds: 6
Polar Surface Area: 98.99Molecular Species: BASEHBA: 7HBD: 3
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 4#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 9.03CX LogP: 5.70CX LogD: 4.23
Aromatic Rings: 4Heavy Atoms: 33QED Weighted: 0.38Np Likeness Score: -1.32

References

1. Kułaga D, Drabczyk AK, Satała G, Latacz G, Rózga K, Plażuk D, Jaśkowska J..  (2022)  Design and synthesis of new potent 5-HT7 receptor ligands as a candidate for the treatment of central nervous system diseases.,  227  [PMID:34710746] [10.1016/j.ejmech.2021.113931]

Source